Inspection Details
The US FDA conducted the inspection at Auroactive Pharma's manufacturing facility located at Sy Nos 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam District, 523 409, Andhra Pradesh. The inspection period was from June 22, 2026, to June 26, 2026.
Facility Operations
The subsidiary manufactures Active Pharmaceutical Ingredients (API) & Pharmaceutical Formulation Intermediates.
Inspection Outcome
The inspection concluded with 2 observations. The company has committed to responding to these observations within the stipulated timeframe.
Financial and Operational Impact
The company explicitly states: "There is no impact on the Company's financials or operations due to the said action."
Date of Receipt
The company received communication regarding the inspection conclusion on June 26, 2026.
Company Commitment
The company states its commitment to maintaining the highest quality manufacturing standards and will keep the stock exchanges informed of any further developments related to this matter.
#Tags: #AurobindoPharma #USFDA #RegulatoryCompliance #SEBIDisclosure #Neutral